Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Cash & Equivalents (2022 - 2025)

Praxis Precision Medicines has reported Cash & Equivalents over the past 4 years, most recently at $357.3 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $357.3 million for Q4 2025, up 65.91% from a year ago — trailing twelve months through Dec 2025 was $357.3 million (up 65.91% YoY), and the annual figure for FY2025 was $357.3 million, up 65.91%.
  • Cash & Equivalents for Q4 2025 was $357.3 million at Praxis Precision Medicines, up from $149.5 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for PRAX hit a ceiling of $357.3 million in Q4 2025 and a floor of $56.0 million in Q2 2022.
  • Median Cash & Equivalents over the past 4 years was $134.7 million (2023), compared with a mean of $134.8 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 164.91% in 2024 and later decreased 11.34% in 2025.
  • Praxis Precision Medicines' Cash & Equivalents stood at $61.6 million in 2022, then surged by 31.95% to $81.3 million in 2023, then soared by 164.91% to $215.4 million in 2024, then skyrocketed by 65.91% to $357.3 million in 2025.
  • The last three reported values for Cash & Equivalents were $357.3 million (Q4 2025), $149.5 million (Q3 2025), and $157.4 million (Q2 2025) per Business Quant data.